All In Biotech

Drug Trial Radar · NCT07348601

A Study of CSTI-500 in Patients With Prader-Willi Syndrome

A Proof-of-Concept Open-Label Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of CSTI-500 in Participants With Prader-Willi Syndrome

Last checked: Nov 19, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

12

Planned (sponsor's estimate)

Start

May 18, 2026

Primary completion

Jun 2027

Study completion Jun 2027

Sponsor

Lead sponsor
ConSynance TherapeuticsIndustry
Sponsor type
Industry
First posted
Jan 16, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 13 years, up to 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a proof-of-concept, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of CSTI-500 in participants with genetically confirmed Prader-Willi Syndrome (PWS) who are 13 to 50 years of age. Participants will receive increasing doses of CSTI-500, and blood levels will be measured to guide individualized dosing.

Conditions

  • Prader-Willi Syndrome

Interventions

  • CSTI-500Drug

    CSTI-500 given orally in an open-label, dose-escalation design with individualized dosing.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of treatment-emergent adverse events (TEAEs)Time frame: 14 weeks
  2. Proportion achieving target CSTI-500 steady-state Cmax with PK-guided dose individualizationTime frame: 12 weeks
  3. Incidence of clinically significant findings in laboratory valuesTime frame: 12 weeks
  4. Incidence of clinically significant findings in 12-lead electrocardiograms (ECGs)Time frame: 12 weeks
  5. Incidence of clinically significant findings in vital signsTime frame: 12 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Vanderbilt University Medical Center

    Nashville, Tennessee · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.